• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Ahmedabad, Sept. 25

Zydus Cadila has received an approval from the USFDA for hydroxychloroquine sulfate tablets in the strength of 200 mg. The drug falls in the DMARD (Disease Modifying Anti-Rheumatic Drug) segment and is used in the treatment of rheumatoid arthritis. The sales of this drug in the US market in 2006 as per NDC Health were estimated at $30 million, the company said in a release here today. The company will market the drug through its US subsidiary, Zydus Pharmaceuticals (USA) Inc. The group has 27 approvals since the commencement of filing process in fiscal 2003-04. So far, it has filed 65 ANDAs (abbreviated new drug applications) and 55 DMFs (drug master files). —

Our Bureau

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Hind Unilever’s buyback plan to begin on Oct 3

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line